Bacterial surface display of endoglin by antigen 43 induces antitumor effectiveness via bypassing immunotolerance and inhibition of angiogenesis

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1981-1990

  Huang, Feng Ying ^a   Li, Ling ^a,b   Liu, Quan ^a,c   Li, Yue Nan ^a   Bai, Rui Zhen ^a,c   Huang, Yong Hao ^a   Zhao, Huan Ge ^a   Guo, Jun Li ^a   Zhou, Song Lin ^a   Wang, Hua ^a   Lin, Ying Ying ^a   Tan, Guang Hong ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Soochow University   (China)

Author keywords

angiogenesis; antigen 43 surface display system (Ag43 system); endoglin; immune tolerance; recombinant vaccine

Indexed keywords

ANGIOGENESIS; ANTIGEN 43 SURFACE DISPLAY SYSTEM (AG43 SYSTEM); ENDOGLIN; IMMUNE TOLERANCE; RECOMBINANT VACCINE;

ADHESINS, ESCHERICHIA COLI; ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; CANCER VACCINES; CARCINOMA, LEWIS LUNG; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; IMMUNE TOLERANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS;

EID: 84893784782     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28511     Document Type: Article

References (43)

1. Owen P,. The gram-negative outer membrane: structure, biochemistry and vaccine potential. Biochem Soc Trans 1992; 20: 1-6.
2. Henderson IR, Navarro-Garcia F, Nataro JP,. The great escape: structure and function of the autotransporter proteins. Trends Microbiol 1998; 6: 370-8. (Pubitemid 28473198)
3. Hasman H, Chakraborty T, Klemm P,. Antigen-43-mediated autoaggregation of Escherichia coli is blocked by fimbriation. J Bacteriol 1999; 181: 4834-41. (Pubitemid 29383511)
4. Diderichsen B,. flu, a metastable gene controlling surface properties of Escherichia coli. J Bacteriol 1980; 141: 858-67. (Pubitemid 10106292)
5. Kjaergaard K, Schembri MA, Hasman H, et al. Antigen 43 from Escherichia coli induces inter- and intraspecies cell aggregation and changes in colony morphology of Pseudomonas fluorescens. J Bacteriol 2000; 182: 4789-96. (Pubitemid 30641800)
6. Kjaergaard K, Hasman H, Schembri MA, et al. Antigen 43-mediated autotransporter display, a versatile bacterial cell surface presentation system. J Bacteriol 2002; 184: 4197-204. (Pubitemid 34774300)
7. Bussolati B, Grange C, Camussi G,. Tumor exploits alternative strategies to achieve vascularization. FASEB J 2011; 25: 2874-82.
8. Risau W,. Mechanisms of angiogenesis. Nature 1997; 386: 671-4. (Pubitemid 27193480)
9. Folkman J,. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
10. Letamendia A, Lastres P, Botella LM, et al. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 1998; 273: 33011-9. (Pubitemid 28557696)
11. Fonsatti E, Nicolay HJ, Altomonte M, et al. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-9.
12. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-7. (Pubitemid 351551101)
13. Tan GH, Wei YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34: 2012-21. (Pubitemid 39256082)
14. Weltzin R, Guy B, Thomas WD, et al. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000; 68: 2775-82. (Pubitemid 30253855)
15. Tan GH, Tian L, Wei YQ, et al. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 2004; 112: 701-6. (Pubitemid 39425953)
16. Czerkinsky CC, Nilsson LA, Nygren H, et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983; 65: 109-21. (Pubitemid 14203438)
17. Huang FY, Li YN, Mei WL, et al. Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis. Asian Pac J Trop Med 2012; 5: 169-74.
18. Huang FY, Mei WL, Li YN, et al. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. Eur J Cancer 2012; 48: 2260-9.
19. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-75. (Pubitemid 36019421)
20. Bodey B, Bodey B, Jr., Siegel SE, et al. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 1998; 18: 2701-10. (Pubitemid 28386569)
21. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-34. (Pubitemid 26030991)
22. Wang JM, Kumar S, Pye D, et al. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993; 54: 363-70. (Pubitemid 23169671)
23. Uneda S, Toi H, Tsujie T, et al. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 2009; 125: 1446-53.
24. Matsuno F, Haruta Y, Kondo M, et al. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371-82. (Pubitemid 29085191)
25. Rosen LS, Hurwitz HI, Wong MK, et al. A phase 1 first-in-human study of TRC105 (anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012; 18: 4820-9.
26. Jiao JG, Li YN, Wang H, et al. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006; 38: 578-87. (Pubitemid 44356254)
27. Wood LM, Pan ZK, Guirnalda P, et al. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother 2011; 60: 931-42.
28. Lee SH, Mizutani N, Mizutani M, et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 2006; 55: 1565-74. (Pubitemid 44327844)
29. Zheng S, Weng Z, Guo J, et al. Anti-tumor angiogenesis with a recombinant ag43/FGFR1 chimeric protein as a model antigen. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 25-8.
30. King J, Waxman J, Stauss H,. Advances in tumour immunotherapy. QJM 2008; 101: 675-83.
31. Schlom J, Arlen PM, Gulley JL,. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007; 13: 3776-82. (Pubitemid 47037581)
32. O'Neill DW, Adams S, Bhardwaj N,. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235-46. (Pubitemid 39331818)
33. Parmiani G, De Filippo A, Novellino L, et al. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007; 178: 1975-9. (Pubitemid 46233392)
34. Palucka K, Ueno H, Banchereau J,. Recent developments in cancer vaccines. J Immunol 2011; 186: 1325-31.
35. Buonaguro L, Petrizzo A, Tornesello ML, et al. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18: 23-34.
36. Cao Y, Arbiser J, D'Amato RJ, et al. Forty-year journey of angiogenesis translational research. Sci Transl Med 2011; 3: 114rv3.
37. Scappaticci FA,. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-27.
38. Tan GH, Su JM, Wang CC, et al. A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma. Int Arch Allergy Immunol 2008; 145: 313-23.
39. Vernersson M, Ledin A, Johansson J, et al. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J 2002; 16: 875-7.
40. Hertz M, Mahalingam S, Dalum I, et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001; 167: 3792-9. (Pubitemid 32910824)
41. Wood PA, Bove K, You S, et al. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther 2005; 4: 1065-75. (Pubitemid 41079100)
42. Fraser HM, Lunn SF,. Angiogenesis and its control in the female reproductive system. Br Med Bull 2000; 56: 787-97. (Pubitemid 32041668)
43. Reynolds LP, Killilea SD, Redmer DA,. Angiogenesis in the female reproductive system. FASEB J 1992; 6: 886-92.